23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Shake Shack

Shares of upscale burger chain Shake Shack have wiped out last year's losses, while 23andMe stock set a record low.

Shake Shack Stock Blows Through the Roof. 23andMe Tumbles.

With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of these conditions With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of these conditions

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

Illumina

Myriad Genetics

Genes are the foundation of human life. They are the code that gives every instruction to our bodies about how to move, digest and think.

3 Gene Testing Stocks to Buy Before They Take Off

23andMe entered its IPO with two down years on revenue but has since reclaimed low double-digit growth. Throughout this time, however, the company has not made identifiable progress toward profitability on either an accrual or cash basis. It continues to use cash from the IPO for operations. This makes for a hold rating even though it is operating in a significant growth market, consumer genetics testing, that has a CAGR of over 20%.

23andMe: Revenue Growth And Secular Trend, But Lack Of Profits Makes It A Hold

23andMe Holding Co. (NASDAQ:ME ) Q4 2023 Results Conference Call May 25, 2023 4:30 PM ET Company Participants Maeve Conneighton - Investor Relations at Argo Partners Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Daniel Grosslight - Citi Steven Mah - Cowen Operator Hello, and welcome to 23andMe's Fiscal Year 2023 Fourth Quarter and Full Year Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe Holding Co. (ME) Q4 2023 Earnings Call Transcript

Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Fulgent Genetics

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business.

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

Ginkgo Bioworks Holdings

Schrodinger 

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

3 Key Biotech Trends for 2023 And Beyond

Bionano Genomics

Precigen

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient's complete health picture

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

23andMe+ members can now gain insights on the chronic autoimmune condition 23andMe+ members can now gain insights on the chronic autoimmune condition

23andMe Releases New Report Revealing Likelihood of Developing Lupus

Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced results from the Phase 1 portion of its Phase 1/2a study evaluating 23ME-00610, an investigational antibody targeting CD200R1. 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target. Based on the Phase 1 data, a dose of 23ME-00610 given at 1400 mg intravenously every 3 weeks was selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a (Phase 2a) 23ME-00610 study.

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

23andMe is known around the world for its ancestry DNA genetic testing service. The company's pivot into therapeutics seems attractive.

23andMe Holding: At Risk Of Becoming Irrelevant

ESG report outlines strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations SOUTH SAN FRANCISCO, Calif. , March 29, 2023 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today published its inaugural environmental, social and governance (ESG) report.

23andMe Publishes Inaugural Environmental, Social and Governance Report

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apple

Artificial intelligence tools could lead to tremendous growth for some companies. 23andMe is already turning its genetic data into pipeline projects at a rapid clip.

AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023

SUNNYVALE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- A large percentage of people and doctors in the US say that using genetic testing could make healthcare more personalized and effective, according to new surveys by 23andMe.

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

Viatris

There's nothing better than getting a bargain that'll pay off for years.

2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise

23andMe has made many strategic acquisitions that have helped the company expand and grow. The genomics industry as a whole is expected to have rapid growth in the future due to the convenience of testing kits as well as the decreased prices.

23andMe Looking Promising For The Long Term

Inmode Ltd

Both are likely to double quite soon, and they aren't even that risky.

2 High-Growth Stocks That Could Double Your Money in 5 Years or Less

The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610 The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

News for 23andMe Stock (ME)